AstraZeneca PLC - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
AZN Nasdaq 2830 www.astrazeneca.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for AstraZeneca PLC

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio - May 15th, 2025 1:40 pm
AstraZeneca’s growth prospects are as attractive as ever. Keep buying - May 14th, 2025 6:19 am
Is AstraZeneca (AZN) the Best Pharma Stock to Invest in Amid the Domestic Manufacturing Boom? - May 13th, 2025 8:59 pm
AstraZeneca to showcase latest research on comprehensive portfolio and pipeline aimed at transforming respiratory diseases at ATS 2025 - May 13th, 2025 11:00 am
MHRA approves AstraZeneca’s Trixeo Aerosphere inhaler for COPD - May 13th, 2025 9:10 am
London stocks strike month-high after US-China tariff deal - May 12th, 2025 4:20 pm
Trump’s Vow to Cut US Drug Prices Drags Pharma Stocks Lower - May 12th, 2025 11:38 am
Trump’s Plan to Cut Drug Prices Hits Pfizer, Other Pharma Stocks - May 12th, 2025 11:33 am
AstraZeneca’s Imfinzi combo shows DFS improvement in bladder cancer trial - May 12th, 2025 11:15 am
Pharma Shares Fall Pre-Bell Following Plan by Trump to Reduce US Prescription Drug Prices - May 12th, 2025 9:55 am
Pharmaceutical Stocks Tumble on Trump Plan to Cut US Drug Prices - May 12th, 2025 8:28 am
AstraZeneca (LSE:AZN) Reports Positive Results From Phase III IMFINZI Trial In Bladder Cancer - May 10th, 2025 5:19 pm
How Much Upside is Left in Astrazeneca (AZN)? Wall Street Analysts Think 27.89% - May 9th, 2025 1:55 pm
Pharma Stock Roundup: NVO & JAZZ's Q1 Results, AZN's Pipeline Update - May 9th, 2025 12:51 pm
IMFINZI® (durvalumab) regimen demonstrated statistically significant and clinically meaningful improvement in disease-free survival for high-risk non-muscle-invasive bladder cancer in POTOMAC Phase III trial - May 9th, 2025 11:00 am
AstraZeneca and Daiichi’s Enhertu shows pCR rate improvement in breast cancer trial - May 8th, 2025 9:37 am
AstraZeneca (LSE:AZN) Reports Positive Phase 3 Trial Results For Breast Cancer Treatment - May 7th, 2025 6:02 pm
Q1 2025 Arcus Biosciences Inc Earnings Call - May 7th, 2025 2:14 pm
Expediting parallel drug approval pathways is challenging, but rewarding - May 7th, 2025 11:04 am
ENHERTU® (fam-trastuzumab deruxtecan-nxki) followed by THP before surgery showed statistically significant and clinically meaningful improvement in pathologic complete response in high-risk HER2-positive early-stage breast cancer in DESTINY-Breast11 - May 7th, 2025 11:00 am